-
An Integrated Cancer Prevention Strategy: the Viewpoint of the Leon Berard Comprehensive Cancer Center Lyon, France Cancer Prev. Res. (IF 3.3) Pub Date : 2024-04-02 Beatrice Fervers, Olivia Pérol, Christine Lasset, Nora Moumjid, Pauline Vidican, Pierre Saintigny, Juliette Tardy, Julien Biaudet, Valérie Bonadona, Dominique Triviaux, Philippe Marijnen, Rodolf Mongondry, Anne Cattey-Javouhey, Romain Buono, Amandine Bertrand, Perrine Marec-Bérard, Christine Rousset-Jablonski, Frank Pilleul, Veronique Christophe, Magali Girodet, Delphine Praud, Marie-Laure Solodky
This article describes some of the key prevention services in the Leon Berard Comprehensive Cancer Center (CLB) Lyon, France, which are based on clinical prevention services, outreach activities, and collaboration with professional and territorial health communities. In addition, research is embedded at all stages of the prevention continuum, from understanding cancer causes through to the implementation
-
Trends in colorectal cancer screening from the National Health Interview Survey (NHIS): analysis of the impact of different modalities on overall screening rates Cancer Prev. Res. (IF 3.3) Pub Date : 2024-04-02 Derek W. Ebner, Lila J. Finney Rutten, Lesley-Ann Miller-Wilson, Niels Markwat, Vahab Vahdat, A. Burak Ozbay, Paul J. Limburg
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in adults in the United States. Despite compelling evidence of improved outcomes in CRC, screening rates are not optimal. This study aimed to characterize CRC screening trends over the last two decades and assess the impact of various screening modalities on overall CRC screening rates. Using National Health Interview Survey
-
Circulating microRNA signature predicts cancer incidence in Lynch syndrome – a pilot study Cancer Prev. Res. (IF 3.3) Pub Date : 2024-03-29 Tero Sievänen, Tiina Jokela, Matti Hyvärinen, Tia-Marje Korhonen, Kirsi Pylvänäinen, Jukka-Pekka Mecklin, Juha Karvanen, Elina Sillanpää, Toni T. Seppälä, Eija K. Laakkonen
Lynch syndrome (LS) is the most common autosomal dominant cancer syndrome and is characterized by high genetic cancer risk modified by lifestyle factors. This study explored whether a circulating microRNA (c-miR) signature predicts LS cancer incidence within a 4-year prospective surveillance period. To gain insight how lifestyle behavior could affect LS cancer risk, we investigated whether the cancer-predicting
-
Low-Carbohydrate Diet Score and Risk of Hepatocellular Carcinoma: Findings from a Prospective Cohort Study Cancer Prev. Res. (IF 3.3) Pub Date : 2024-03-26 Yen Thi-Hai. Pham, Aizhen Jin, Renwei Wang, Jaideep Behari, Woon-Puay Koh, Jian-Min Yuan, Hung N. Luu
Limited data are reported on the association between low-carbohydrate diet (LCD) score, a comprehensive measure of dietary pattern according to sources of carbohydrate, fat and protein, and risk of hepatocellular carcinoma (HCC). We evaluated this score with HCC risk in the Singapore Chinese Health Study, a prospective cohort of 63,275 middle-aged and elderly Chinese living in Singapore and recruited
-
Fenretinide in young women at genetic or familial risk of breast cancer: A placebo-controlled biomarker trial Cancer Prev. Res. (IF 3.3) Pub Date : 2024-03-26 Valentina Aristarco, Davide Serrano, Patrick Maisonneuve, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Irene Feroce, Debora Macis, Elena Cavadini, Elena Albertazzi, Costantino Jemos, Emanuela Omodeo Salè, Laura Cortesi, Samuele Massarut, Marcella Gulisano, Maria Grazia. Daidone, Harriet Johansson, Bernardo Bonanni
Fenretinide, a retinoid with a low toxicity profile that accumulates in the breast, has been shown to prevent second breast cancer in young women. Fenretinide exhibits apoptotic and anti-invasive properties and it improves insulin sensitivity in overweight premenopausal women with insulin resistance. The present study aimed to further characterize its role in cancer prevention by measuring circulating
-
Combination of an autoantibody panel and alpha-fetoprotein for early detection of hepatitis B virus-associated hepatocellular carcinoma Cancer Prev. Res. (IF 3.3) Pub Date : 2024-03-15 Yajing Shen, Jiajun Chen, Jinyu Wu, Tiandong Li, Chuncheng Yi, Keyan Wang, Peng Wang, Changqing Sun, Hua Ye
The purpose of this study was to identify biomarkers associated with hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) and to develop a new combination with good diagnostic performance. This study was divided into four phases: discovery, verification, validation and modeling. A total of four candidate tumor-associated autoantibodies (TAAbs) (anti-ZIC2, anti-PCNA, anti-CDC37L1, and anti-DUSP6)
-
Engaging Communities in Cancer Prevention and Control Activity Prioritization through a Statewide Needs Assessment: A Case Study from Nebraska Cancer Prev. Res. (IF 3.3) Pub Date : 2024-03-04 Shinobu Watanabe-Galloway, Krishtee Napit, Jordan McCullough, Lady Beverly Luma, Josiane Kabayundo, Nicole L. Carritt, Laura Schabloske, Tamara Robinson, Jolene Rohde, Victoria Champion, Noelle K. LoConte, Kendra L. Ratnapradipa
Community outreach and engagement (COE) activities are important in identifying catchment area needs, communicating these needs, and facilitating activities relevant to the population. The National Cancer Institute–designated cancer centers are required to conduct catchment-wide cancer needs assessments as part of their COE activities. The University of Nebraska Medical Center Buffett Cancer Center
-
Next-Generation Screening for Colorectal Cancer, an Incremental Approach to a Global Disease Cancer Prev. Res. (IF 3.3) Pub Date : 2024-03-04 Robert S. Bresalier
New screening tests for early detection of colorectal cancer and its precursors are rapidly emerging with the focus on noninvasive tests which can be used in both structured opportunistic and population-based organized screening programs. Novel technologies are identifying new combinations of promising markers. Conducting large prospective clinical trials of efficacy requires very large numbers of
-
High-Fat Diet Induced PPARδ Promotes Self-renewal of Preleukemic Progenitors in Development of Acute Promyelocytic Leukemia Cancer Prev. Res. (IF 3.3) Pub Date : 2024-02-02 Hiroshi Y. Yamada, Chinthalapally V. Rao
From risk association between acute promyelocytic leukemia (APL) and obese-overweight individuals, Mazzarella and colleagues hypothesized that a high-fat diet (HFD) promotes development of APL. Using mouse APL model (PML-RARα knock-in), the authors demonstrated that linoleic acid drives activation of PPARδ in hematopoietic progenitors, and that activation of PPARδ increases proliferation of progenitor
-
The Effects of Black Raspberry as a Whole Food-Based Approach on Biomarkers of Oxidative Stress in Buccal Cells and Urine of Smokers Cancer Prev. Res. (IF 3.3) Pub Date : 2024-01-30 Kun-Ming Chen, Yuan-Wan Sun, Nicolle M. Krebs, Lisa Reinhart, Dongxiao Sun, Jiangang Liao, Rachel Cook, Paige Elizabeth. Bond, Susan R. Mallery, Karam El-Bayoumy
Cigarette smoke is a rich source of free radicals that can promote oxidative stress and carcinogenesis including head and neck squamous cell carcinoma (HNSCC) development; importantly, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and 8-iso-prostaglandin F2α (8-isoprostane) are biomarkers of oxidative stress. Several mechanisms including the antioxidant properties of black raspberry (BRB) account for
-
IDENTIFICATION OF A BIOMARKER PANEL FROM GENOME-WIDE METHYLATION TO DETECT EARLY HPV-ASSOCIATED OROPHARYNGEAL CANCER Cancer Prev. Res. (IF 3.3) Pub Date : 2024-01-30 Brittney L. Dickey, Ryan M. Putney, Michael J. Schell, Anders E. Berglund, Antonio L. Amelio, Jimmy J. Caudell, Christine H. Chung, Anna R. Giuliano
As oropharyngeal cancer (OPC) associated with human papillomavirus (HPV) increases in men, the need for a screening test to diagnose OPC early is crucial. This study agnostically identified differentially methylated CpG sites to identify additional biomarkers to improve screening for early OPC. DNA was extracted from oral gargles of 89 early cases and 108 frequency matched healthy controls, and processed
-
The Past and Future of Inflammation as a Target to Cancer Prevention Cancer Prev. Res. (IF 3.3) Pub Date : 2024-01-25 Laura Antonucci, Michael Karin
Inflammation is an essential defense mechanism in which innate immune cells are coordinately activated on encounter of harmful stimuli, including pathogens, tissue injury, and toxic compounds and metabolites to neutralize and eliminate the instigator and initiate healing and regeneration. Properly terminated inflammation is vital to health, but uncontrolled runaway inflammation that becomes chronic
-
Green Cancer Prevention and Beyond Cancer Prev. Res. (IF 3.3) Pub Date : 2024-01-22 Sharon A. Ross, Nancy J. Emenaker, Amit Kumar, Gabriela Riscuta, Kajal Biswas, Shanker Gupta, Altaf Mohammed, Robert H. Shoemaker
The concept of green chemoprevention was introduced in 2012 by Drs. Jed Fahey and Thomas Kensler as whole plant foods and/or extract based interventions demonstrating cancer prevention activity. Refining concepts and research demonstrating proof of principle approaches are highlighted within this review. Early approaches included extensively investigated whole foods, including broccoli sprouts and
-
Next-generation multi-target stool DNA panel accurately detects colorectal cancer and advanced precancerous lesions Cancer Prev. Res. (IF 3.3) Pub Date : 2024-01-15 Zubin D. Gagrat, Martin Krockenberger, Abhik Bhattacharya, Bridget Z. Gagrat, Christine M. Leduc, Michael B. Matter, Keith D. Fourrier, Douglas W. Mahoney, David K. Edwards, Graham P. Lidgard, Paul J. Limburg, Scott C. Johnson, Michael J. Domanico, John B. Kisiel
The multi-target stool DNA (mt-sDNA) test screens for colorectal cancer (CRC) by analyzing DNA methylation/mutation and hemoglobin markers to algorithmically derive a qualitative result. A new panel of highly discriminant candidate methylated DNA markers (MDMs) was recently developed. Performance of the novel MDM panel, with hemoglobin, was evaluated in a simulated screening population using archived
-
Acceptability of Personalized Lung Cancer Screening Program Among Primary Care Providers Cancer Prev. Res. (IF 3.3) Pub Date : 2024-01-12 Paul J. Resong, Jiangong Niu, Gabrielle F. Duhon, Lewis E. Foxhall, Sanjay Shete, Robert J. Volk, Iakovos Toumazis
Current lung cancer screening (LCS) guidelines rely on age and smoking history. Despite its benefit, only 5-15% of eligible patients receive LCS. Personalized screening strategies select individuals based on their lung cancer risk and may increase LCS’s effectiveness. We assess current LCS practices and the acceptability of personalized LCS among primary care providers (PCP) in Texas. We surveyed 32
-
Leveraging GWAS: Path to Prevention? Cancer Prev. Res. (IF 3.3) Pub Date : 2024-01-04 Stacey J. Winham, Mark E. Sherman
Developing novel cancer prevention medication strategies is important for reducing mortality. Identification of common genetic variants associated with cancer risk suggests the potential to leverage these discoveries to define causal targets for cancer interception. Although each risk variant confers small increases in risk, researchers propose that blocking those that produce causal carcinogenic effects
-
Utilizing Human Genetics to Develop Chemoprevention for Cancer—Too Good an Opportunity to be Missed Cancer Prev. Res. (IF 3.3) Pub Date : 2024-01-04 Ulrike Peters, Ian Tomlinson
Large-scale genetic studies are reliably identifying many risk factors for disease in the general population. Several of these genetic risk factors encode potential drug targets, and genetics has already helped to introduce targeted agents for some diseases, an example being lipid-lowering drugs to reduce the incidence of cardiovascular disease. Multiple drugs have been developed to treat cancers based
-
Recent American College of Physicians Guidance Statement for Screening Average-risk, Asymptomatic Adults for Colorectal Cancer Cancer Prev. Res. (IF 3.3) Pub Date : 2024-01-04 Ernest T. Hawk, Stephanie L. Martch
The American College of Physicians (ACP) update of their standing guidance statement for colorectal-cancer screening in asymptomatic average-risk adults was recently published to assist clinicians with implementing evidence-based patient care. After assessing existing guideline literature, the ACP recommended five actions: consider not screening adults ages 45 to 49 years; stop screening adults older
-
Breast Cancer Polygenic Risk Score Influence on Risk-Reducing Endocrine Therapy Use: Genetic Risk Estimate (GENRE) Trial 1-Year and 2-Year Follow-up Cancer Prev. Res. (IF 3.3) Pub Date : 2023-12-28 Daniela L. Stan, Julian O. Kim, Daniel J. Schaid, Erin E. Carlson, Christina A. Kim, Jason P. Sinnwell, Fergus J. Couch, Celine M. Vachon, Andrew Cooke, Benjamin A. Goldenberg, Sandhya Pruthi
Refinement of breast cancer (BC) risk estimates with a polygenic risk score (PRS) may improve uptake of risk-reducing endocrine therapy (ET). A previous clinical trial assessed the influence of adding a PRS to traditional risk estimates on ET use. We stratified participants according to PRS-refined BC risk and evaluated ET use and ET-related quality of life (QOL) at 1-year (previously reported) and
-
Cancer Prevention Perspective: The University of Kansas Cancer Center Cancer Prev. Res. (IF 3.3) Pub Date : 2023-12-01 Roy A. Jensen, Christie A. Befort
Despite the incredible progress that has been made against cancer over the last few decades, the demographic trends in the United States predict that we will see significant increases in cancer incidence and mortality by the year 2030. This, coupled with an aging cancer workforce, would suggest that we will have major challenges ahead in dealing with the increasing burden from cancer. Clearly a critical
-
Treatment of Cervical Precancers is the Major Remaining Challenge in Cervical Screening Research Cancer Prev. Res. (IF 3.3) Pub Date : 2023-12-01 Kanan T. Desai, Silvia de Sanjosé, Mark Schiffman
Deepening understanding of cervical cancer pathogenesis has yielded one-dose prophylactic human papillomavirus (HPV) vaccines and accurate HPV-based cervical screening tests. Knowing the heterogeneous carcinogenic potential of the individual high-risk HPV types permits prioritization of vaccination and screening strategies. However, “correct” (i.e., safe and effective) treatment of women found to have
-
Comparing Breast Cancer and Cardiovascular Disease Risk and Use of Chemoprevention and Statins among Women with High-risk Breast Lesions Cancer Prev. Res. (IF 3.3) Pub Date : 2023-11-17 Kehinde O. Lawal, Luisa Nilan, Jacquelyn Amenta, Julia E. McGuinness, Rita Kukafka, Katherine D. Crew
Breast cancer chemoprevention with selective estrogen receptor modulators (SERM) or aromatase inhibitors (AI) remains underutilized among high-risk women. A potential barrier to chemoprevention is competing comorbidities such as atherosclerotic cardiovascular disease (ASCVD), due to concern for additional medication side effects. We conducted a retrospective cohort study among women with atypical hyperplasia
-
Early-onset colon cancer shows a distinct intestinal microbiome and a host-microbe interaction Cancer Prev. Res. (IF 3.3) Pub Date : 2023-11-16 Darbaz Adnan, Jonathan Q. Trinh, Deepak Sharma, Muhammad Alsayid, Faraz Bishehsari
The incidence rate of colorectal cancer (CRC) in younger adults has been rising in developed countries. This trend may be attributed to environmental exposures as a result of lifestyle changes. Many of the lifestyle factors that promote CRC can also affect the gut microbiome, which may be associated with CRC risks. The role of the microbiome in the ongoing rise of early-onset CRC is unknown. Here,
-
High-fat diet promotes Acute Promyelocytic Leukemia through PPARδ-enhanced self-renewal of preleukemic progenitors Cancer Prev. Res. (IF 3.3) Pub Date : 2023-11-13 Luca Mazzarella, Paolo Falvo, Marta Adinolfi, Giulia Tini, Elena Gatti, Rossana Piccioni, Emanuele Bonetti, Elena Gavilán, Debora Valli, Alicja Gruszka, Margherita Bodini, Barbara Gallo, Stefania Orecchioni, Giulia de Michele, Enrica Migliaccio, Bruno A. Duso, Sophie Roerink, Mike Stratton, Francesco Bertolini, Myriam Alcalay, Gaetano Ivan. Dellino, Pier Giuseppe Pelicci
Risk and outcome of Acute Promyelocytic Leukemia (APL) are particularly worsened in obese-overweight individuals, but the underlying molecular mechanism is unknown. In established mouse APL models (Ctsg-PML::RARA), we confirmed that obesity induced by High-Fat Diet (HFD) enhances leukemogenesis by increasing penetrance and shortening latency, providing an ideal model to investigate obesity-induced
-
Examining the Association between Abstinence from Smoking and Healthcare Costs Among Patients with Cancer Cancer Prev. Res. (IF 3.3) Pub Date : 2023-11-09 George Kypriotakis, Seokhun Kim, Maher Karam-Hage, Jason D. Robinson, Jennifer A. Minnix, Janice A. Blalock, Yong Cui, Diane Beneventi, Bumyang Kim, I-Wen Pan, Ya-Chen Tina. Shih, Paul M. Cinciripini
Continuous tobacco use in cancer patients is linked to substantial healthcare costs due to increased risks and complications, whereas quitting smoking leads to improved treatment outcomes and cost reductions. Addressing the need for empirical evidence on the economic impact of smoking cessation, this study examined the association between smoking cessation and healthcare cost utilization among a sample
-
Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations–A Qualitative Study Cancer Prev. Res. (IF 3.3) Pub Date : 2023-11-02 Erica M. Bednar, J. Alejandro Rauh-Hain, Jose J. Garcia, Norma de Aguinaga, Mary Anne. Powell, Sylvia L. Peral, Roni Nitecki, Kirsten Jorgensen, Natasha L. Rudy, Karen H. Lu, Charles A. Leath, Isabel C. Scarinci
We sought to explore the intrafamilial communication and cascade genetic testing (CGT) experiences of patients with hereditary cancer from diverse, medically underserved populations and their relatives. Participants included patients receiving oncology care at an urban, safety-net hospital in Texas or comprehensive cancer center in Alabama and their first-degree relatives. In-depth semi-structured
-
Rutgers Cancer Institute of New Jersey's Community Outreach and Engagement Approach to Cancer Prevention Cancer Prev. Res. (IF 3.3) Pub Date : 2023-11-01 Anita Y. Kinney, Antoinette M. Stroup, Sarah Scharf, Steven K. Libutti
Rutgers Cancer Institute of New Jersey (New Brunswick, NJ) is committed to providing cancer prevention education, outreach, and clinical services in our catchment area (CA). Our approach to cancer prevention includes ongoing surveillance to better understand the CA cancer burden and opportunities for intervention, leveraging community partnerships, and vigorously engaging diverse communities to understand
-
Preventive Treatment with PD-1 Antibody Increases Tissue-Resident Memory T Cells Infiltration and Delays Esophageal Carcinogenesis Cancer Prev. Res. (IF 3.3) Pub Date : 2023-10-20 Zeru Xiao, Rui Yan, Heshu Liu, Xuying Huang, Ziwei Liang, Guangyu An, Yang Ge
Numerous studies and clinical trials have shown that immune checkpoint inhibitors can effectively prevent tumor growth and metastasis in esophageal squamous cell carcinoma (ESCC) patients. In this study, we aimed to evaluate the anti-tumor effects of PD-1 antibody preventive treatment in patients with early stages ESCC as well as patients with high-grade intraepithelial neoplasia (HGIN). We first established
-
Clinical performance of hrHPV primary screening using vaginal versus cervical samples to detect high-grade intraepithelial lesions Cancer Prev. Res. (IF 3.3) Pub Date : 2023-10-03 Jonathan King, Yvonne N. Flores, Joacim Meneses-León, Sonia Hernández-Salazar, Karina Robles-Rivera, Berenice Rivera-Paredez, Leith León-Maldonado, Rubí Hernández-López, Leticia Torres-Ibarra, Eduardo Lazcano-Ponce, Jorge Salmerón
High-risk human papillomavirus (hrHPV) testing is now the most recommended primary method for cervical cancer screening worldwide. Clinician-collected cervical sampling continues to be the main sampling method, but hrHPV vaginal self-sampling is an appealing alternative because of its greater acceptability and potentially higher cost-effectiveness. This study aimed to determine if hrHPV vaginal self-sampling
-
Alvin J. Siteman Cancer Center: Cancer Prevention Perspective Cancer Prev. Res. (IF 3.3) Pub Date : 2023-10-02 Graham A. Colditz, Bettina F. Drake, Timothy J. Eberlein
We summarize Siteman Cancer Center catchment that covers 82 counties in southern Illinois and eastern Missouri. We note both the high poverty and cancer rates in many rural counties. Siteman Community Outreach and Engagement has developed a number of strategies to move towards achieving health equity. These include NCI-funded research projects in rural clinics and outreach to improve access to cancer
-
Opportunities to Improve HPV Vaccination Among Pediatric, Adolescent, and Young Adult Cancer Survivors by Engaging both Oncology and Primary Care Teams Cancer Prev. Res. (IF 3.3) Pub Date : 2023-10-02 Melinda Butsch Kovacic, Alique Topalian, Melissa Erickson
The incidence of second primary cancers is rising particularly among pediatric, adolescent, and young adult (PAYA) cancer survivors. While human papillomavirus (HPV)-associated cancers can be prevented by vaccination, their uptake is lower and delayed in this group. Because a recommendation from a health care provider is the strongest predictor of HPV vaccination, there are great opportunities for
-
Knowledge Mediates the Effects of Game Changers for Cervical Cancer Prevention (GC-CCP) Intervention on Increased VIA Screening Advocacy in Uganda Cancer Prev. Res. (IF 3.3) Pub Date : 2023-09-28 Glenn J. Wagner, Joseph KB. Matovu, Margrethe Juncker, Eve Namisango, Jolly Beyeza-Kashesya, Rhoda K. Wanyenze
Game Changers for Cervical Cancer Prevention (GC-CCP), a group advocacy training intervention, has been shown to increase cervical cancer (CC) prevention and screening advocacy. In this secondary analysis, we examined mediators and moderators of this effect. A randomized controlled trial of GC-CCP-- a 7-session, peer led intervention designed to empower women to engage in CC prevention advocacy—was
-
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial Cancer Prev. Res. (IF 3.3) Pub Date : 2023-09-27 Vinicius F. Calsavara, Norah L. Henry, Ron D. Hays, Sungjin Kim, Michael Luu, Márcio A. Diniz, Gillian Gresham, Reena S. Cecchini, Greg Yothers, Patricia A. Ganz, André Rogatko, Mourad Tighiouart
Predicting an individual’s risk of treatment discontinuation is critical for the implementation of precision chemoprevention. We developed partly conditional survival models to predict discontinuation of tamoxifen or anastrozole using patient-reported outcome (PRO) data from postmenopausal women with ductal carcinoma in situ (DCIS) enrolled in the NSABP B-35 clinical trial. In a secondary analysis
-
Polymorphisms in Cyclooxygenase, Lipoxygenase and TP53 genes predict colorectal polyp risk reduction by aspirin in the seAFOod polyp prevention trial Cancer Prev. Res. (IF 3.3) Pub Date : 2023-09-27 John R. Davies, Tracey Mell, Harriett Fuller, Mark Harland, Rasha NM. Saleh, Amanda D. Race, Colin J. Rees, Louise C. Brown, Paul M. Loadman, Amy Downing, Anne Marie Minihane, Elizabeth A. Williams, Mark A. Hull
Aspirin and eicosapentaenoic acid (EPA) reduce colorectal adenomatous polyp risk and affect synthesis of oxylipins including prostaglandin E2. We investigated whether 35 single nucleotide polymorphisms (SNPs) in oxylipin metabolism genes such as cyclooxygenase [PTGS] and lipoxygenase [ALOX], as well as 7 SNPs already associated with colorectal cancer (CRC) risk reduction by aspirin (eg. TP53; rs104522)
-
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients Cancer Prev. Res. (IF 3.3) Pub Date : 2023-09-21 Carlos L. Arteaga, John L. Cleveland, Margaret Foti, Ruben A. Mesa, Louis M. Weiner, Cheryl L. Willman, David A. Tuveson
Basic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers
-
Methylated DNA Markers for Sporadic Colorectal and Endometrial Cancer Are Strongly Associated with Lynch Syndrome Cancers Cancer Prev. Res. (IF 3.3) Pub Date : 2023-09-20 Rachel M. Bramblet, Jamie N. Bakkum-Gamez, Seth W. Slettedahl, Patrick H. Foote, William R. Taylor, Calise K. Berger, Brianna J. Gysbers, Jacquelyn Arndt, Longwen Chen, Karen A. Doering, Kelli N. Burger, Douglas W. Mahoney, Mark E. Sherman, John B. Kisiel, N. Jewel Samadder
Lynch syndrome (LS) markedly increases risks of colorectal and endometrial cancers. Early detection biomarkers for LS cancers could reduce the needs for invasive screening and surgical prophylaxis. To validate a panel of methylated DNA markers (MDM) previously identified in sporadic colorectal cancer and endometrial cancer for discrimination of these cancers in LS. In a case–control design, previously
-
A Novel Saliva and Serum miRNA Panel as a potential useful index for Oral Cancer and the Association of miR-21 with smoking history: a pilot study Cancer Prev. Res. (IF 3.3) Pub Date : 2023-09-08 Dimitra P. Vageli, Panagiotis G. Doukas, Rema Shah, Trinithas Boyi, Christina Liu, Benjamin L. Judson
Tobacco use is implicated in the carcinogenesis of oral squamous cell carcinoma (OSCC), which is associated with poor survival if not diagnosed early. Identification of novel non-invasive, highly sensitive, and cost-effective diagnostic and risk assessment methods for OSCC would improve early detection. Here, we report a pilot study assessing salivary and serum miRNAs associated with OSCC and stratified
-
Risk Stratification for Early-onset Colorectal Cancer Screening: Are We Ready for Implementation? Cancer Prev. Res. (IF 3.3) Pub Date : 2023-09-01 Erin M. Siegel, Cornelia M. Ulrich, David Shibata
Early-onset colorectal cancer (EOCRC) is increasing at alarming rates and identifying risk factors is a high priority. There is a need to develop risk stratification approaches for colorectal cancer screening among younger populations. Although there is a growing body of evidence identifying risk factors for EOCRC, including the report by Imperiale and colleagues in this issue, risk stratification
-
Protein advanced glycation end products and their implications in pancreatic cancer Cancer Prev. Res. (IF 3.3) Pub Date : 2023-08-14 Lakmini Senavirathna, Sheng Pan, Ru Chen
Protein advanced glycation end products (AGEs) formed by non-enzymatic glycation can disrupt the normal structure and function of proteins, and stimulate the receptor for AGEs (RAGE), triggering intricate mechanisms that are etiologically related to various chronic diseases, including pancreatic cancer. Many common risk factors of pancreatic cancer are the major sources for the formation of protein
-
Psychosocial Risk Profiles and Colorectal Cancer Screening: A Latent Profile Analysis in a Colorectal Cancer Screening Intervention Setting Cancer Prev. Res. (IF 3.3) Pub Date : 2023-08-08 Navkiran K. Shokar, Alok Dwivedi, Jennifer C. Molokwu
Health behavior theories have identified predictors of colorectal cancer screening. This study aimed to determine the psychosocial profiles of a predominantly Hispanic population of primarily Mexican origin receiving a colorectal cancer screening intervention and whether a specific combination of psychosocial profiles modified the effect of colorectal cancer screening intervention on colorectal cancer
-
Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection Cancer Prev. Res. (IF 3.3) Pub Date : 2023-07-21 Nina Rao, Gabriel J. Starrett, Mary L. Piaskowski, Kelly E. Butler, Yelena Golubeva, Wusheng Yan, Scott M. Lawrence, Michael Dean, Montserrat Garcia-Closas, Dalsu Baris, Alison Johnson, Molly Schwenn, Nuria Malats, Francisco X. Real, Manolis Kogevinas, Nathaniel Rothman, Debra T. Silverman, Lars Dyrskjøt, Christopher B. Buck, Stella Koutros, Ludmila Prokunina-Olsson
FGFR3 and PIK3CA are among the most frequently mutated genes in bladder tumors. We hypothesized that recurrent mutations in these genes might be caused by common carcinogenic exposures such as smoking and other factors. We analyzed 2,816 bladder tumors with available data on FGFR3 and/or PIK3CA mutations, focusing on the most recurrent mutations detected in ≥10% of tumors. Compared to tumors with other
-
Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines Cancer Prev. Res. (IF 3.3) Pub Date : 2023-07-20 Konstantin H. Dragnev, Ronald A. Lubet, Mark Steven Miller, Shizuko Sei, Jennifer T. Fox, Ming You
Therapeutic targeting of RAS-mutated cancers is difficult, whereas prevention or interception (treatment before or in the presence of preinvasive lesions) preclinically has proven easier. In the A/J mouse lung model, where different carcinogens induce tumors with different KRAS mutations, glucocorticoids and retinoid X receptor (RXR) agonists are effective agents in prevention and interception studies
-
Association and Prediction Utilizing Craniocaudal and Mediolateral Oblique View Digital Mammography and Long-Term Breast Cancer Risk Cancer Prev. Res. (IF 3.3) Pub Date : 2023-07-10 Simin Chen, Rulla M. Tamimi, Graham A. Colditz, Shu Jiang
Mammographic percentage of volumetric density is an important risk factor for breast cancer. Epidemiology studies historically used film images often limited to craniocaudal (CC) views to estimate area-based breast density. More recent studies using digital mammography images typically use the averaged density between craniocaudal (CC) and mediolateral oblique (MLO) view mammography for 5- and 10-year
-
TIME for Bugs: The Immune Microenvironment and Microbes in Precancer Cancer Prev. Res. (IF 3.3) Pub Date : 2023-07-10 Mikayla Borthwick Bowen, Beth A. Helmink, Jennifer A. Wargo, Melinda S. Yates
Major advances in our understanding of the tumor immune microenvironment (TIME) in established cancer have been made, including the influence of host-intrinsic (host genomics) and -extrinsic factors (such as diet and the microbiome) on treatment response. Nonetheless, the immune and microbiome milieu across the spectrum of precancerous tissue and early neoplasia is a growing area of interest. There
-
Rates of Intervention and Cancer Detection on Initial versus Subsequent Whole-body MRI Screening in Li-Fraumeni Syndrome Cancer Prev. Res. (IF 3.3) Pub Date : 2023-07-10 Laura A.T. Kagami, Yun K. Du, Conrad J. Fernandes, Anh N. Le, Madeline Good, Melani M. Duvall, Sarah E. Baldino, Jacquelyn Powers, Kristin Zelley, Lisa J. States, Manoj C. Mathew, Bryson W. Katona, Suzanne P. MacFarland, Kara N. Maxwell
Li-Fraumeni Syndrome (LFS) is a hereditary cancer predisposition syndrome with up to 90% lifetime cancer risk. Cancer screening, including annual whole-body MRI (WB-MRI), is recommended due to known survival advantage, with cancer detection rate of 7% on initial screening. Intervention and cancer detection rates on subsequent screenings are unknown. Clinical data for pediatric and adult patients with
-
PreCancer Atlas: Present and Future Cancer Prev. Res. (IF 3.3) Pub Date : 2023-07-05 Sudhir Srivastava, Paul D. Wagner, Shannon K. Hughes, Sharmistha Ghosh
Precancer atlases have the potential to revolutionize how we think about the topographic and morphologic structures of precancerous lesions in relation to cellular, molecular, genetic, and pathophysiologic states. This mini review uses the Human Tumor Atlas Network (HTAN), established by the National Cancer Institute (NCI), to illustrate the construction of cellular and molecular three-dimensional
-
From Premalignant Biology to Precision Interception: Connecting the Dots with a Curated Collection of Invited Articles Cancer Prev. Res. (IF 3.3) Pub Date : 2023-07-05 Karen Colbert Maresso, Anirban Maitra, Ernest T. Hawk, Eduardo Vilar
Nearly all cancers have identifiable histologically defined precursors known as precancers. These precancers offer a window of opportunity to intercept the neoplastic process to prevent its development into invasive cancer. However, lack of knowledge regarding the evolution of precancers and the microenvironmental pressures shaping them precludes efforts to intercept them. Technological developments
-
Avoiding Low-Value Care and Patient Financial Harm in Cervical Cancer Screening Cancer Prev. Res. (IF 3.3) Pub Date : 2023-07-05 George F. Sawaya, Vanessa G. Dorismond
The provision of low-value care remains a significant concern in healthcare. The negative impacts resulting from low-value cervical cancer screenings are extensive at the population level and can lead to harms and substantial out-of-pocket expenses for patients. Inattention to the financial implications of screening poses a serious threat to low-income populations that depend on affordable screening
-
Vaccination and Microbiota Manipulation Approaches for Colon Cancer Prevention in Rodent Models Cancer Prev. Res. (IF 3.3) Pub Date : 2023-06-27 Elena Tosti, Nityanand Srivastava, Winfried Edelmann
Colorectal cancer represents the third most common cancer type worldwide and is a leading cause of cancer-related mortality in the United States and Western countries. Rodent models have been invaluable to study the etiology of colorectal cancer and to test novel chemoprevention avenues. In the past, the laboratory mouse has become one of the best preclinical models for these studies due to the availability
-
Progressive Spreading of DNA Methylation in the GSTP1 Promoter CpG Island across Transitions from Precursors to Invasive Prostate Cancer Cancer Prev. Res. (IF 3.3) Pub Date : 2023-06-23 Harshath Gupta, Hitoshi Inoue, Yasutomo Nakai, Masashi Nakayama, Tracy Jones, Jessica L. Hicks, Balasubramanian Kumar, Meltem Gurel, William G. Nelson, Angelo M. De Marzo, Srinivasan Yegnasubramanian
Glutathione S-transferase pi 1 (GSTP1) is lowly expressed in normal prostate luminal cells and becomes induced in most proliferative inflammatory atrophy (PIA) lesions. GSTP1 becomes silenced in prostatic intraepithelial neoplasia (PIN) and prostate adenocarcinoma (CaP) via cytosine-phospho-guanine (CpG) island promoter hypermethylation. However, GSTP1 methylation patterns in PIA and PIN, and their
-
Liver Fibrosis Scores and Prostate Cancer Risk and Mortality in the Atherosclerosis Risk in Communities Study Cancer Prev. Res. (IF 3.3) Pub Date : 2023-06-20 Anqi Wang, Mariana Lazo, Jiayun Lu, David J. Couper, Anna E. Prizment, Mara Z. Vitolins, Samuel R. Denmeade, Corinne E. Joshu, Elizabeth A. Platz
Subclinical liver impairment due to fibrosis could influence the development and detectability of prostate cancer. To investigate the association between liver fibrosis and prostate cancer incidence and mortality, we included 5,284 men (mean age: 57.6 years, 20.1% Black) without cancer or liver disease at Visit 2 in the Atherosclerosis Risk in Communities study. Liver fibrosis was assessed using the
-
Examining the Barriers and Opportunities for Human Papillomavirus Vaccine Delivery in Cancer Care Settings: A Mixed-Methods Study Cancer Prev. Res. (IF 3.3) Pub Date : 2023-06-01 Melany A. Garcia, Nicolas F. Schlecht, Denise A. Rokitka, Kristopher M. Attwood, Elisa M. Rodriguez
Although pediatric, adolescent, and young adult (PAYA) cancer survivors are at increased risks for secondary cancers, their HPV vaccine uptake rates are poor. Therefore, we conducted a mixed-methods study to identify the barriers and opportunities for HPV vaccine delivery among PAYA cancer care providers. We distributed a semistructured questionnaire to a professional organization comprised of PAYA
-
A Systematic Review and Pooled Analysis of Hypothesized versus Observed Effect Sizes in Early Phase Cancer Prevention Clinical Trials Cancer Prev. Res. (IF 3.3) Pub Date : 2023-06-01 Jens Eickhoff, Jen Zaborek, Guanhua Chen, Vikrant V. Sahasrabuddhe, Leslie G. Ford, Eva Szabo, KyungMann Kim
Early phase cancer prevention trials are designed to demonstrate safety, tolerability, feasibility, and signals of efficacy of preventive agents. Yet it is often observed that many trials fail to detect intervention effects. We conducted a systematic review and pooled analyses of recently completed early phase chemoprevention trials to gain in depth insight on the failure of detecting efficacy signals
-
Reproductive Events and Risk of Women's Cancers: From Parturition to Prevention Cancer Prev. Res. (IF 3.3) Pub Date : 2023-06-01 Mark E. Sherman, Miriam Levi, Lauren R. Teras
Reproductive events beginning with pregnancy and ending with remodeling of the breast after cessation of breastfeeding alter breast structure and function and produce dramatic changes in systemic biology. In aggregate, these processes lower overall risk for breast, tubo-ovarian and endometrial cancers, albeit differentially by molecular subtypes of these tumors. Herein, we explore opportunities for
-
Categorizing Risks within Barrett's Esophagus To Guide Surveillance and Interception; Suggesting a New Framework Cancer Prev. Res. (IF 3.3) Pub Date : 2023-06-01 Judith Honing, Rebecca C. Fitzgerald
Barrett's esophagus is a precancerous condition that can progress in a stepwise manner to dysplasia and eventually esophageal adenocarcinoma (EAC). Once diagnosed, patients with Barrett's esophagus are kept on surveillance to detect progression so that timely intervention can occur with endoscopic therapy. Several demographic and clinical risk factors are known to increase progression toward EAC, such
-
Pancreatic Cancer Disparities among Gender, Race, and Ethnicity: The PRECEDE Consortium Outcomes and Impact Cancer Prev. Res. (IF 3.3) Pub Date : 2023-06-01 Hiroshi Y. Yamada, Chinthalapally V. Rao
The Pancreatic Cancer Early Detection (PRECEDE) Consortium was launched internationally to assess the surveillance of high-risk individuals (HRI) of pancreatic cancer, focusing on genetic risk factors. In the early recruitment period of 3 years from May 2020 to March 2022, the PRECEDE gathered analysis-eligible data on 1,113 HRIs. In this issue of Cancer Prevention Research, Katona and colleagues reported
-
Associations between Physical Activity and Incidence of Cancer among Overweight Adults in Korea: Results from the Health Examinees-G Study Cancer Prev. Res. (IF 3.3) Pub Date : 2023-05-23 Jaesung Choi, JooYong Park, Ji-Eun Kim, Miyoung Lee, Daehee Kang, Aesun Shin, Ji-Yeob Choi
Although the protective effects of physical activity against several cancers are well established, evidence is inconsistent concerning Asian populations. Therefore, we assessed the association between the characteristics of physical activity and overall and type-specific cancer incidence in Koreans and examined the differences in association according to obesity status. Using prospective data from
-
Polymorphisms in the Nonhomologous End-joining DNA Repair Pathway are Associated with HPV Integration in Cervical Dysplasia Cancer Prev. Res. (IF 3.3) Pub Date : 2023-05-23 Jennifer M. Geris, E. Susan Amirian, Deborah A. Marquez-Do, Martial Guillaud, Laura M. Dillon, Michele Follen, Michael E. Scheurer
Previous evidence indicates that human papillomavirus (HPV) integration status may be associated with cervical cancer development and progression. However, host genetic variation within genes that may play important roles in the viral integration process is understudied. The aim of this study was to examine the association between HPV16 and HPV18 viral integration status and SNPs in nonhomologous-end-joining
-
Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening Cancer Prev. Res. (IF 3.3) Pub Date : 2023-05-21 Diane M. Harper, Rye J. Anderson, Ed Baker, Tiffany M. Yu
The first biomarker-based cervical cancer screening test, p16/Ki-67 dual-stained cytology (DS), has been clinically validated and approved in the United States for triage of women being screened for cervical cancer who test positive for high-risk human papillomavirus (hrHPV). The primary aim of this work is to evaluate the cost-effectiveness of DS triage after co-testing findings of positive non-16/18
-
Advances in Mapping Tumor Progression from Precancer Atlases Cancer Prev. Res. (IF 3.3) Pub Date : 2023-05-11 Zhengyi Chen, Ken S. Lau
Tissue profiling technologies present opportunities for understanding transition from precancerous lesions to malignancy, which may impact risk stratification, prevention, and even cancer treatment. A human precancer atlas building effort is ongoing to tackle the significant challenge of decoding the heterogeneity among cells, specimens, and patients. Here, we discuss the findings resulting from atlases